AN2 Therapeutics Inc
General ticker "ANTX" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $42.6M
AN2 Therapeutics Inc does not follow the US Stock Market performance with the rate: -31.6%.
Estimated limits based on current volatility of 4.0%: low 1.25$, high 1.36$
Factors to consider:
- Current price 87.1% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [10.88$, 24.23$]
- 2024-12-30 to 2025-12-30 estimated range: [7.32$, 17.68$]
Short-term ANTX quotes
Long-term ANTX plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $21.57MM | $42.26MM | $69.64MM |
| Operating Income | $-21.57MM | $-42.26MM | $-69.64MM |
| Non-Operating Income | $0.03MM | $1.31MM | $4.90MM |
| Interest Expense | $0.00MM | $0.51MM | $0.00MM |
| R&D Expense | $16.91MM | $29.51MM | $54.87MM |
| Income(Loss) | $-21.54MM | $-40.96MM | $-64.73MM |
| Profit(Loss) | $-21.54MM | $-40.96MM | $-64.73MM |
| Stockholders Equity | $-47.41MM | $95.37MM | $124.70MM |
| Assets | $65.32MM | $102.56MM | $138.74MM |
| Operating Cash Flow | $-20.48MM | $-33.46MM | $-53.29MM |
| Investing Cash Flow | $-50.02MM | $-21.77MM | $-43.28MM |
| Financing Cash Flow | $78.53MM | $70.36MM | $84.99MM |
| Earnings Per Share* | $-1.15 | $-2.14 | $-2.74 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.